PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.15
Negative D/E while AGEN shows 0.26. Joel Greenblatt would look for hidden assets and restructuring catalysts.
0.94
Net debt 50-75% of AGEN's 1.12. Mohnish Pabrai would check if this competitive advantage in leverage translates to better reinvestment opportunities.
-7936.02
Both companies show negative coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
0.78
Current ratio below 50% of AGEN's 4.62. Jim Chanos would check for potential working capital crisis.
No Data
No Data available this quarter, please select a different quarter.